Indian stocks: Visit www.stage2stocks.com →

Innate Pharma S.A.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Innate Pharma is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $1.50, 40.8% below its 52-week high and below its 200-day average, which is falling.

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. More about the company

$1.50
-4.46% today
$168M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is IPHA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S4 29w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 1w → S3 2w → S4 16w → S1 12w → S4 9w → S1 2w → S2 1w → S1 2w → S4 11w → S1 5w → S4 13w → S1 1w → S4 3w → S1 11w → S2 11w → S3 6w → S2 8w → S3 3w → S4 29w → S1 6w → S2 13w → S3 2w current
Total tracked: 166 weeks across 22 stage runs.

IPHA among Biotechnology278th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…278IPHAStage 3 · wk 334−14.8%
vs 52W High
-40.8%
$1.17 lo$2.54 hi
40.8% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 3
1w13w26w
Week 3, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-12.9%
200 DMA: $1.72 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.59x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-14.8%
3M
-15.7%
6M
+9.5%
YTD
-17.6%
1Y
-28.6%
Scan Membership
Breakout Watch
Latest: 2025-04-24
5 appearances in last 60 days. First seen: 2021-09-23.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 3 · Vol 0.59x
2026-10-21S3
Wk 3 · Vol 0.28x
2026-10-20S3
Wk 3 · Vol 0.07x
2026-10-19S3
Wk 2 · Vol 0.04x
2026-10-16S3
Wk 2 · Vol 0.04x
2026-10-15S3
Wk 2 · Vol 0.04x
2026-10-14S3
Wk 2 · Vol 0.05x
2026-10-13S3
Wk 2 · Vol 0.03x
2026-10-12S3
Wk 1 · Vol 0.17x
2026-10-09S3
Wk 1 · Vol 0.24x
2026-10-08S3
Wk 1 · Vol 0.09x
2026-10-07S3
Wk 1 · Vol 0.07x
Moving averages & range
50 DMA
$1.85
200 DMA
$1.72
52W High
$2.54
52W Low
$1.17
5D Low
$1.43
Resistance levels (recent highs)
20d High
$1.70
60d High
$2.54
120d High
$2.54
250d High
$2.54
Next resistance
+13.3%
to 20d High
Dividend Yield
0.00%
P/B -3.1

Innate Pharma: quick answers

What stage is Innate Pharma in?

As of Oct 22, 2026, Innate Pharma (IPHA) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Innate Pharma in an uptrend?

Its uptrend has stalled. Innate Pharma is in Stage 3, the topping phase that follows an advance. It trades 12.9% below its 200-day average, which is falling.

How far is Innate Pharma from its 52-week high?

Innate Pharma closed at $1.50 on Oct 22, 2026, 40.8% below its 52-week high of $2.54. Its 52-week low is $1.17.

How has Innate Pharma performed over the past year?

As of Oct 22, 2026, Innate Pharma is down 28.6% over the past year and down 17.6% so far in 2026.

Which sector and industry is Innate Pharma in?

Innate Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.